This is a Class I recall, which means using the devices “may cause serious injuries or death.” The catheter's instructions have been updated to reduce the risk of complications going forward. 

If successful, the group's first-in-class medication would be able to target inflammation in CVD patients before it even occurs. 

The new device, the first of its kind to gain FDA approval, was designed for patients who have no other endovascular or surgical options available to them.

The study’s authors examined data from more than 15,000 patients who had their first intracerebral hemorrhage from January 2003 to December 2021

The ILUMIEN IV and OCTOBER trials helped illustrate that the benefits of intravascular ultrasound also are seen with optical coherence tomography. Both trials were included in the new meta-analysis presented at ESC Congress 2023.

The ACC has joined forces with Amgen and Esperion Therapeutics to increase LDL screening in patients with and without a history of cardiovascular issues.

Researchers examined data from more than 1,300 procedures, presenting their findings in JACC: Cardiovascular Interventions.